Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15.04. | Glenmark announces recall of high blood pressure medication in US | 69 | Pharmaceutical Technology | ||
14.04. | Glenmark recalls 6,528 bottles of blood pressure drug in US | 403 | ZEE Business | ||
12.04. | NTPC, Glenmark Pharma among 5 stocks with long buildup | 101 | Times of India | ||
10.04. | Lupin, Glenmark recall drugs in US market: USFDA | 134 | ZEE Business | ||
05.04. | Glenmark Pharmaceuticals Ltd up for five straight sessions | 48 | capitalmarket.com | ||
11.03. | Glenmark Pharmaceuticals Ltd gains for third straight session | 2 | capitalmarket.com | ||
23.02. | F&O stocks: Trent, Glenmark Pharma among 5 stocks with short buildup | 2 | Times of India | ||
20.02. | India's Glenmark Pharma could see better operating margins, says HSBC; hikes PT | 3 | Reuters | ||
20.02. | Hot Stocks: Brokerage view on Kotak Mahindra, Glenmark Pharma, Biocon and RIL | 4 | Times of India | ||
16.02. | India's Glenmark Pharma set for best 2-day gain in 3 yrs on upbeat results, forecast | 1 | Reuters | ||
16.02. | BPCL, Glenmark Pharma among 5 stocks with long buildup | 2 | Times of India | ||
15.02. | Glenmark Pharma reports net loss of Rs 331 cr in Q3 FY24 | 2 | capitalmarket.com | ||
15.02. | Glenmark Pharma trades higher despite pharma firm reports loss in December quarter | 2 | ZEE Business | ||
14.02. | Glenmark Q3 Results: Co reports net loss of Rs 351 cr on lower domestic sales | 2 | Times of India | ||
14.02. | Glenmark Q3 results: Company reports net loss of Rs 351 crore on lower domestic sales | 2 | ZEE Business | ||
13.02. | Glenmark Pharmaceuticals Ltd drops for fifth straight session | 2 | capitalmarket.com | ||
31.01. | Glenmark Pharma hits 52-week high on forming alliance to develop cancer drug | 2 | capitalmarket.com | ||
25.01. | Glenmark bags subcutaneous checkpoint inhibitor, moving to turf targeted by Big Pharma | 2 | FierceBiotech | ||
25.01. | Glenmark Pharmaceuticals Ltd: Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World | 278 | PR Newswire | Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. Jiangsu Alphamab... ► Artikel lesen | |
25.01. | Glenmark licenses cancer drug from China's Alphamab, 3D Med | 4 | pharmaphorum |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SINOPHARM | 2,548 | +1,39 % | Aktie der Sinopharm Group läuft heute schlechter (2,31 €) | Im Minus liegt aktuell die Aktie der Sinopharm Group . Das Papier kostete zuletzt 2,31 Euro. Die Sinopharm Group-Aktie verzeichnet derzeit einen Kursverlust von 3,63 Prozent. Sie hat sich um 9 Cent... ► Artikel lesen | |
CSPC PHARMA | 0,709 | 0,00 % | Minimale Kursveränderung bei Aktie der CSPC Pharmaceutical Group (0,7154 €) | Wenig Kursbewegung derzeit bei dem Anteilsschein der CSPC Pharmaceutical Group . Das Wertpapier kostete zuletzt 0,72 Euro. Kaum auffällig ist aktuell an der Börse der Kurs der CSPC Pharmaceutical Group.... ► Artikel lesen | |
WUXI BIOLOGICS | 1,520 | -2,06 % | Wuxi Biologics Cayman-Aktie mit großen Kursgewinnen (1,6496 €) | Im Wertpapierhandel brilliert derzeit das Wertpapier von Wuxi Biologics Cayman . Der Kurs der Aktie legt kräftig zu. Eine Steigerung um 5,74 Prozent - mit diesem Preisanstieg gehört der Anteilsschein... ► Artikel lesen | |
SHANGHAI FOSUN PHARMACEUTICAL | 1,371 | -2,77 % | FOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE ACCEPTANCE OF A SUBSIDIARY'S DRUG REGISTRATION APPLICATION | ||
DR REDDYS | 67,50 | +1,50 % | Dr Reddy's recalls six lots of drug in US due to subpotency | ||
GEDEON RICHTER | 22,840 | +4,96 % | Aktien Osteuropa Schluss: Börsen schließen überwiegend mit Gewinnen | PRAG/BUDAPEST/WARSCHAU (dpa-AFX) - Die wichtigsten Börsen in Mittel- und Osteuropa haben am Donnerstag überwiegend mit Gewinnen schlossen. Lediglich in Budapest ging es nach unten. Am deutlichsten... ► Artikel lesen | |
ASPEN PHARMACARE | 10,200 | -0,97 % | ASPEN PHARMACARE HOLDINGS LIMITED - Completion of two Transactions with Sandoz | ||
SHANGHAI PHARMACEUTICALS | 1,320 | +0,76 % | SH PHARMA (02607): NOTICE OF BOARD MEETING | ||
LUYE PHARMA | 0,316 | +1,28 % | LUYE PHARMA (02186): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023 | ||
SIHUAN PHARMACEUTICAL HOLDINGS GROUP | 0,056 | -1,75 % | SIHUAN PHARM Annual Loss Narrows to RMB54.017M | ||
CHINA SHINEWAY PHARMACEUTICAL GROUP | 1,070 | 0,00 % | SHINEWAY PHARM (02877): 2023 ANNUAL RESULTS ANNOUNCEMENT AND DECLARATION OF 2024 FIRST INTERIM DIVIDEND | ||
CHINA RESOURCES PHARMACEUTICAL | 0,570 | +0,88 % | CHINARES PHARMA (03320): ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF CR BOYA BIO-PHARMACEUTICAL FOR THE THREE MONTHS ENDED 31 MARCH 2024 | ||
HANSOH PHARMACEUTICAL | 1,900 | -2,56 % | HANSOH PHARMA (03692): NEXT DAY DISCLOSURE RETURN | ||
YICHANG HEC CHANGJIANG PHARMACEUTICAL | - | - | HEC CJ PHARM (01558): JOINT ANNOUNCEMENT MONTHLY UPDATE PURSUANT TO RULE 3.7 OF THE TAKEOVERS CODE IN RELATION TO THE POSSIBLE MERGER OF THE COMPANY | ||
KALBE FARMA | 0,075 | +0,67 % | Allocating IDR 1 trillion, KLBF to set buyback of 625 million shares: PT Kalbe Farma Tbk (KLBF) is allocating ... |